Xiaoyao pill for treatment of functional dyspepsia in perimenopausal women with depression

AIM: To evaluate the efficacy and safety of the Xiaoyao pill for treatment of functional dyspepsia(FD) associated with perimenopausal depression.METHODS: This was a double-blind, randomized, controlled trial including 180 patients with FD accompanied by depression that were divided into two groups of 90. Patients in the treatment group received oral administration of the Xiaoyao pill for soothing the liver and activating the spleen, and patients in the control group received a placebo. This trial included an 8-wk therapy period with a follow-up period of 6 mo. The total efficacy and degree of depression, as assessed by the Hamilton Rating Scale for Depression(HRSD), were evaluated. Plasma levels of motilin and gastrin were measured and a gastric emptying test was conducted in each participant.RESULTS:The Xiaoyao pill had a good therapeutic effect and improved the symptoms in patients with perimenopausal FD as assessed by the HRSD score,motilin and gastrin levels,and rate of gastric emptying.The total effective rate of the Xiaoyao pill in the treatment group was significantly superior to that of the placebo in the control group.In the control group,the initial HRSD score was 12.12±2.29 and decreased to7.14±1.67 after therapy(P<0.01).In the treatment group,the initial HRSD score was 11.44±2.15,which significantly decreased to 6.20±2.08 after therapy(P<0.01).Moreover,the HRSD score in the treatment group was significantly lower than in control group after 8 wk(P<0.01).Motilin and gastrin levels in both groups were significantly increased after the 8-wk therapy(P<0.05).The gastric emptying rate was also improved in both groups after therapy(P<0.05),and the improvement was significantly better in the treatment group compared to the controls(P<0.05).These results confirm the therapeutic effects of the Xiaoyao pill in perimenopausal FD patients and indicate that it is worthy of clinical promotion.CONCLUSION:The Xiaoyao pill is effective and safe for the treatment of perimenopausal women with FD ass